There are articles that actually break out Sales & Marketing budgets (2013 numbers I am excluding J&J since they have a lot of consumer products) "Next in line

There are articles that actually break out Sales & Marketing budgets (2013 numbers I am excluding J&J since they have a lot of consumer products) "Next in line is Pfizer ($PFE), long known for its marketing muscle. The drugmaker plowed $11.4 billion into marketing in 2013, $4.8 billion more than it spent on R&D--a difference of 72%. AstraZeneca ($AZN) is close behind with a 70% difference. The U.K.-based company put $7.3 billion toward marketing last year, and $4.3 billion into R&D. AstraZeneca has been pumping up marketing behind products such as its blood-thinner Brilinta as it preps for the onslaught of Nexium copycats. The next 5 range from a 47% difference in favor of R&D on the high end--Novartis ($NVS), with $14.6 billion in marketing spending--to 27% on the low end. The latter is Merck ($MRK), with $9.5 billion allocated to marketing and $7.5 billion to R&D. Then there's Eli Lilly ($LLY), with a mere $200 million premium to the marketing side. Its marketing spending clocked in at $5.7 billion, compared with $5.5 billion for R&D. That's a difference of just 7%.""